source
- Alzheon seeks up to $500M in new financing after Phase 3 setback for Alzheimer’s drugAlzheon, a biotech based in Framingham, Massachusetts, has been pursuing an Alzheimer’s therapy for more than a decade. Its lead candidate recently failed to achieve the primary goals in a Phase 3…
- mRNA cancer vaccines’ biggest barriers to marketManufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.